Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, reported financial results for the twelve months ended December 31, 2017, in an amendment filed with the SEC on Thursday.
It originally set terms for a $55 million IPO in January, but postponed the deal a few weeks later. In the updated filing, Entera removed its proposed terms and added warrants to the offering. Maxim Group LLC will now serve as sole bookrunner on the deal.
Entera Bio was founded in 2009 and plans to list on the Nasdaq under the symbol ENTX.
